ivosidenib — CareFirst (Caremark)

Initial criteria

• Treatment of conventional (grades 1–3) or dedifferentiated chondrosarcoma in members with a susceptible IDH1 mutation

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months